HUTCHMED ADR Aktie

 

The average of price targets set by Wall Street analysts indicates a potential upside of 73.5% in HUTCHMED (HCM). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock....

The mean of analysts' price targets for HUTCHMED (HCM) points to a 68.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock....

HUTCHMED (00013.HK) recently announced the latest research results of its Phase III clinical trial in China for the combined therapy of savolitinib and osimertinib for the treatment of non-small cell lung cancer at the ASCO Annual Meeting. The interim analysis results show that the combination of savolitinib and osimertinib demo......

HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that the New Drug Application for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma (RCC) who have failed prior treatment with one tyrosine kinase inhibitor has been accepted for r......

HUTCHMED (00013.HK) and INNOVENT BIO (01801.HK) jointly announced that their new drug application for the combination therapy of fruquintinib and sintilimab has been accepted by China's National Medical Products Administration.This therapy is intended for the treatment of patients with locally advanced or metastatic renal ce......

BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) and Innovent Biologics, Inc. announced that the New Drug Application (NDA) for the combination of fruquintinib and sintilimab for the treatment o......

SAN FRANCISCO and SUZHOU, China, June 4, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic,......

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801) today jointly announce that the New Drug Application (“NDA”) for the combination of fruquintinib and sintilimab for the treatment of patients with locally advanced or metastatic renal cell carcinoma who have failed prior treatment with one tyrosine kinase inhibitor (“TKI”) has been accepted for review by the China National Medical Products Administration (“NMPA”)....

BEIJING (dpa-AFX) - HUTCHMED (China) Limited (HCM) announced that results from the SACHI Phase III study represent a significant advancement in the treatment of EGFR mutation-positive NSCLC with M......

— The all-oral chemotherapy-free combination of savolitinib plus osimertinib demonstrated significant PFS benefit with a favorable safety profile in the SACHI Phase III China study —...

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., May 23, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new data from several studies of compounds discovered by HUTCHMED including savolitinib, ranosidenib, fruquintinib and surufatinib, will be presented at the American Society of Clinical Oncology (“ASCO”) Annual Meeting taking place on May 30 – June 3, 2025 in Chicago, USA....

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., April 24, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by HUTCHMED including savolitinib, fruquintinib and surufatinib, which will be presented at the upcoming American Association of Cancer Research (AACR) Annual Meeting 2025, taking place on April 25-30, 2025 in Chicago, Illinois....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

The following stocks are the leading risers and fallers on AIM on Tuesday.----------AIM - WINNERS----------Hutchmed China Ltd, up 9.0% at 231.00 pence, 12-month range 185.50p-353.00p.......

HONG KONG and FLORHAM PARK, N.J., April 22, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed enrollment of the registration phase of its Phase II trial of savolitinib in gastric cancer patients with MET amplification....

Blood-cancer medicine, manufactured in the US, won conditional approval for sale in mainland China last month....

HUTCHMED (00013.HK) delivered strong 2024 results, benefiting from strong overseas sales of its FRUZAQLA (fruquintinib), which drove turnover growth, CMBI released a research report saying. Revenue from oncology/ immunology products grew 65% YoY to US$272 million, exceeding the previous guidance of 30-50% growth.In parallel with......

BEIJING (dpa-AFX) - HUTCHMED China (HCM) announced that the New Drug Application for TAZVERIK has been granted conditional approval in China for the treatment of adult patients with relapsed or re......

— First and only EZH2 inhibitor approved by the NMPA —...

Daiwa released a report maintaining its Buy rating on HUTCHMED (00013.HK), while cutting the target price from HKD36 to HKD33. The globalization of the company’s product Fruzaqla continues to progress, with ATTC showing advancements. The 2025 guidance includes consolidated oncology/ IO revenue of USD350-450 million. Due to......